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Abstract
Background and purpose: Silent cerebral infarcts (SCIs) are the most common neurological complication in
children and adults with sickle cell disease (SCD). In this systematic review, we provide an overview of studies that
have detected SCIs in patients with SCD by cerebral magnetic resonance imaging (MRI). We focus on the frequency
of SCIs, the risk factors involved in their development and their clinical consequences.
Methods: The databases of Embase, MEDLINE ALL via Ovid, Web of Science Core Collection, Cochrane Central
Register of Trials via Wiley and Google Scholar were searched from inception to June 1, 2019.
Results: The search yielded 651 results of which 69 studies met the eligibility criteria. The prevalence of SCIs in
patients with SCD ranges from 5.6 to 80.6% with most studies reported in the 20 to 50% range. The pooled
prevalence of SCIs in HbSS and HbSβ0 SCD patients is 29.5%. SCIs occur more often in patients with the HbSS and
HbSβ0 genotype in comparison with other SCD genotypes, as SCIs are found in 9.2% of HbSC and HbSβ+ patients.
Control subjects showed a mean pooled prevalence of SCIs of 9.8%. Data from included studies showed a
statistically significant association between increasing mean age of the study population and mean SCI prevalence.
Thirty-three studies examined the risk factors for SCIs. The majority of the risk factors show no clear association with
prevalence, since more or less equal numbers of studies give evidence for and against the causal association.
Conclusions: This systematic review and meta-analysis shows SCIs are common in patients with SCD. No clear risk
factors for their development were identified. Larger, prospective and controlled clinical, neuropsychological and
neuroimaging studies are needed to understand how SCD and SCIs affect cognition.
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Background
Sickle cell disease (SCD) is an autosomal recessive
haemoglobinopathy characterized by ongoing haemolytic
anaemia, episodes of vaso-occlusion and progressive
organ failure. Millions are affected worldwide, and ap-
proximately 312.000 neonates with this haematological
disorder are born annually [1]. SCD is caused by a single
nucleotide substitution in codon 6 of the β-globin gene.
This mutation leads to the formation of abnormal
haemoglobin, called HbS [2]. When deoxygenated, HbS
erythrocytes become sickle or crescent-shaped, rigid and
prone to lysis. These sickle cells interact with leukocytes
and the vascular endothelium causing occlusion and vas-
culopathy, subsequently leading to a broad range of
acute and chronic complications including cerebrovascu-
lar disease [3, 4].
The most common neurological complication in chil-
dren and adults with SCD is the development of silent
cerebral infarcts (SCIs), also referred to as silent strokes
[5–7]. In contrast to the clinically overt strokes, SCIs do
not lead to apparent focal neurological symptoms and
can only be detected with neuroimaging techniques [8,
9]. As a consequence, SCIs are identified incidentally or
through screening. Although SCIs do not lead to any
tangible motor or sensory deficits, they are associated
with cognitive morbidity and an increased risk of future
strokes [10–12]. SCIs are visible as focal lesions on both
computed tomography (CT) scans and magnetic reson-
ance imaging (MRI) scans. Detection is however better
by MRI due to the greater range of contrast between soft
tissues and greater detail in the depiction of intracranial
structures [13].
There is an ongoing debate over the rationale of
screening for SCIs in patients with SCD [14, 15]. While
the Silent Cerebral Infarct Transfusion (SIT) randomized
controlled trial showed that chronic red blood cell trans-
fusions reduce the risk of recurrent infarction, this bene-
fit was incomplete with some children in the transfusion
therapy arm also developing infarct recurrence [16].
More importantly, the true incidence and prevalence of
SCIs remain unknown and the understanding of the
pathophysiology and risk factors limited. In this system-
atic review, we provide an overview of studies that have
used brain MRI studies to detect SCIs in patients with
SCD while focusing on the frequency of SCIs, the risk
factors potentially involved in their occurrence and their
clinical impact. Emphasis is placed on the epidemiology




For this report, the Preferred Reporting Items for System-
atic Reviews and Meta-Analyses (PRISMA) guidelines
were followed [17]. A comprehensive systematic search
was performed in Embase, MEDLINE ALL via Ovid, Web
of Science Core Collection, Cochrane Central Register of
Trials via Wiley and Google Scholar (Additional file 1)
from inception to June 1, 2019. Search terms included
multiple synonyms for ‘SCIs’, ‘SCD’ and ‘MRI’ in various
combinations. No limitations in the search strategy were
inserted. The search strategy was designed and conducted
by an experienced librarian (W.M.B.) with input from the
primary investigators.
Study selection
Studies were screened on potential eligibility by two in-
dependent reviewers (M.E.H., R.L.G.). Papers had to be
written in English. Studies had to report original data;
reviews, case reports and letters were excluded. Both
controlled studies and (retrospective) cohort studies
were eligible. Studies were included if they involved pa-
tients of all ages with either homozygous or compound
heterozygous SCD without overt stroke and specifically
assessed for detection of SCIs by MRI. Differences of
opinion were resolved by discussion and consensus be-
tween the reviewers.
Data assessment
For each included study, the following information was
collected: study design, characteristics of the patient
population, mean or median age at study inclusion, uti-
lized MRI protocol, additionally performed advanced
MR and ultrasonic imaging techniques, SCI prevalence,
risk factors studied, clinical consequences and other
major observations or conclusions. For any missing in-
formation or unresolved discrepancies, we contacted the
authors of the studies for clarification or to request un-
published data. As it is difficult to determine whether a
focal hyperintensity seen on MRI is caused by actual in-
farction or by another underlying cause (e.g. inflamma-
tion, infection, demyelination) [18], all different terms
used for strongly related MRI findings in included stud-
ies (e.g. white matter hyperintensities, white matter
changes, silent lesions, ischaemic lesions) were consid-
ered to be SCIs. The reviewers read and abstracted each
article, and a third member with specific imaging expert-
ise (M.H.D) checked the table entries for accuracy with
regard to the original articles. Data were reviewed
descriptively.
Where multiple articles were included for a single or
overlapping population sample, prevalence and inci-
dence estimates were obtained from the report with the
largest sample size to prevent duplication.
Statistical methods
Continuous data are presented as mean and range or as
95% confidence intervals (CI), whereas categorical data
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are presented as frequency and proportion (%). The
mean pooled prevalence of SCIs was calculated with uni-
variate general linear models, in which we weighted SCI
prevalence for the sample size of the included studies.
The outcomes are presented as pooled mean prevalence
and 95% CI. We also used univariate general linear
models to compare the mean pooled prevalence of SCIs
between the two independent groups.
The association between the prevalence of SCIs and
age was analysed with linear regression analysis. We ad-
justed the outcomes of the linear regression analysis for
publication year, study design (i.e. prospective cohort
study or retrospective cohort study), sample size and
field strength. The outcomes of the linear regression
analysis are presented as unstandardized beta (β), 95%
CI and p value.
For studies that did not report the mean age of study
participants, grouped data mean calculation formula was
used to calculate the mean. For open-end age intervals
(e.g. < 25 or > 50 years) where it is not possible to
calculate the mean, the median and calculated median of
study participants were applied.
Risk factor analysis
Selected articles were evaluated to identify all studied
risk factors. The reported statistics described in univari-
ate analyses were examined to determine the direction
of the association of a particular risk factor and whether
it was deemed statistically significant. ‘Independent’ risk
factors were identified from studies in which multivari-
able analyses were conducted.
Results
The literature search yielded a total of 651 non-duplicate
citations that were screened using predetermined inclu-
sion and exclusion criteria. A total of 69 full-text articles
met the inclusion criteria for this review. These publi-
cations reported data on the frequency of SCIs in pa-
tients with SCD from 41 studies. Figure 1 shows the
flow chart of articles resulting from the initial search
to the final inclusion or exclusion. Twenty-three stud-
ies were conducted in the USA (58.5%), 14 in Europe,
one in Brazil, one in India, one in Turkey and one in
Kuwait.
Definitions of SCIs and MRI detection
An important finding was the general lack of uniformity
in definitions of SCIs in SCD. Definitions identified were
based on both MRI criteria and clinical characteristics
(e.g. normal neurological examination). In most studies,
SCIs were defined as focal areas of abnormally increased
T2-weighted signal intensity on multiple anatomical
views without associated neurological deficits. Approxi-
mately half of the studies applied a more precise
definition in which a focal brain lesion was required to
be at least 3 or 5 mm in one dimension and visible in
two planes on fluid-attenuated inversion recovery (FLAI
R) T2-weighted images, with a normal neurological
examination. Eight studies did not explicitly state what
the applied definition for SCIs was.
In addition to the varying definitions of SCIs, the de-
tection of SCIs depends on MRI parameters including
magnet strength and spatial resolution (most import-
antly slice thickness). The majority of studies (72%) used
a 1.5-T MRI magnet, a 3.0-T magnet was used in 17% of
studies and the remaining 11% used another magnet
strength (i.e. 0.6 T, 1.0 T, 7.0 T). Slice thickness varied
from 1.0 to 6.0 mm and was not mentioned in 24
(58.5%) studies.
Information concerning MRI parameters—including
magnet strength and sequences—as well as imaging and
clinical criteria used for diagnosis of SCIs, in the 41 in-
cluded studies, is depicted in Table 1.
Additional neuroimaging techniques
Transcranial Doppler
The majority of studies excluded patients with abnormal
transcranial Doppler (TCD) flow velocities (> 170 cm/s)
indicative of an increased risk of overt stroke. Most
studies that concomitantly measured TCD velocities
found no significant differences between the mean TCD
velocities of patients with normal MRI scans and pa-
tients with detected SCIs [6, 23, 57–64]. Moreover, com-
parison of patients who were included in both the
Cooperative Study of SCD (CSSCD) and the Stroke Pre-
vention (STOP) trial showed that patients with abnormal
TCDs did not demonstrate a concurrent high prevalence
of SCIs. Conversely, those who had SCIs did not present
with a high prevalence of abnormally increased TCD
velocities [64].
In contrast, two studies—one retrospective cohort
study and one prospective cohort study—in respectively
254 and 23 SCD patients reported a significant
association between higher (maximum) TCD velocities
and SCIs [24, 55].
Magnetic resonance angiography
More than half of the included studies performed mag-
netic resonance angiography (MRA) as part of the MRI
examination. Some studies found that signs of MRA-
defined cerebral vasculopathy were related to the pres-
ence and/or number of SCIs [6, 20, 24, 58, 63]. In the
Silent Cerebral Infarct Transfusion (SIT) trial, the
frequency of intracranial vasculopathy in patients with
and without SCIs was 15.9% and 6.3%, respectively (p <
0.001). However, the majority (84%) of patients with
SCIs did not show vasculopathy on MRA [63].
Houwing et al. BMC Medicine          (2020) 18:393 Page 3 of 17
Arterial spin labelling
Arterial spin labelling (ASL) provides a method to non-
invasively obtain a quantitative measurement of cerebral
blood flow. The majority of recently performed ASL
studies confirm an elevated global cerebral blood flow in
patients with SCD, with no differences between patients
with and without SCIs [40, 52, 65, 66]. However, a study
by Ford et al. compared cerebral blood flow maps from
children with and without SCIs and found that SCIs
were associated with impaired haemodynamics including
low cerebral blood flow in the region of the highest in-
farct density (p < 0.001) [31].
SCI localization
Approximately 80% of children in whom SCIs were de-
tected in the CSSCD study had abnormalities in the
frontoparietal deep white matter and periventricular re-
gions on MRI, with other infarcts located in the basal
ganglia and the temporal lobe. Infarcts were distributed
equally in both brain hemispheres [8, 10]. Similar obser-
vations were reported in other studies [20, 22, 28, 30, 33,
50, 55, 59, 62]. Both overt strokes and SCIs predomin-
antly occurred in the watershed regions of the deep
white matter and encompassed only 5.6% of the brain
volume [31].
SCI frequency
The prevalence and incidence of SCIs in patients with
SCD varied widely, depending on the study population
and MRI protocol. While most included studies were co-
hort studies, both prospective and retrospective, some
case-control studies and one randomized controlled trial
Fig. 1 Flowchart of publications included in the systematic review. SCD, sickle cell disease; SCIs, silent cerebral infarcts; MRI, magnetic
resonance imaging
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Sequence MRI criteria for SCIs detection Clinical criteria for SCIs
Abboud et al.
2011 [19]
– 5.0 T1: ax | FLAIR: ax,
cor
Evidence of cerebral infarction on MRI No history of overt stroke
Arkuszewski
et al. 2014 [20]
3.0 T – FLAIR Area of abnormal hyperintensity,





1.5 T 5.0 T1: ax, sag | T2:




1.5 T – T1: sag, cor | T2:
ax | FLAIR: cor
Area of abnormal hyperintensity on
T2
No history of a focal neurological deficit
lasting > 24 h
Bernaudin et al.
2011 [23]
1.0 or 1.5 T – T1 | T2 | FLAIR Signal abnormality, ≥ 3 mm in one
dimension, visible on two views on T2
No history of overt stroke and normal
neurologic examination
De Blank et al.
2010 [24]
– – – Evidence of cerebral infarction on MRI No overt neurological symptoms
Brousse et al.
2017 [25]
– – – – –
Brown et al.
2000 [26]




3.0 T – T2 | FLAIR White matter lesions, i.e. poorly
defined hyperintensities, ≥ 5 mm on
T2 or FLAIR




3.0 T 1.0 or 1.3
or 5.0
3D T1 | 3D T2 | ≥ 3 mm lesions on 3D T2 observed in
two orthogonal planes
No history of overt stroke
Dowling et al.
2012 [29]
1.5 or 3.0 T – FLAIR: ax Area of abnormal hyperintensity
intensity in multiple T2
No history or physical findings of a
focal neurological deficit lasting > 24 h
Ford et al.
2017 [30]
– – T1 |FLAIR Area of abnormal hyperintensity on
FLAIR > 3 mm and cerebrospinal fluid-




– – T1 |FLAIR Signal abnormality, ≥ 3 mm in one
dimension, visible on two planes on
FLAIR T2
Normal neurological examination or
absence of neurological symptoms that
correlate with lesion location
Gold et al.
2008 [32]
– – – – –
Guilliams et al.
2015 [33]
1.5 or 3.0 T 5.0 T1: sag | T2: ax
|FLAIR: ax, cor
Signal abnormality, ≥ 3 mm in one
dimension, visible on two planes on
T2 or FLAIR
Absence of neurological symptoms that
correlate with lesion location
Gyang et al.
2011 [34]
– – – Abnormal MRI changes No neurological symptoms
Issar et al.
2018 [35]
1.5 T – T1: ax | T1 FLAIR:
sag | T2: ax
|FLAIR: ax
Areas of abnormal hyperintensity on
FLAIR T2








1.5 T – T2: ax – –
Kwiatkowski
et al. 2009 [6]
1.5 T – FLAIR Area of abnormal hyperintensity on
T2 and FLAIR
No history of overt stroke or motor




1.5 T 5.0 T1: sag, ax | T2:
sag, ax | PD: ax
Abnormal MRI No history or physical findings of a
focal neurological deficit lasting > 24 h
Mercuri et al.
1995 [39]
1.0 T 6.0 T2 – –
Oguz et al.
2003 [40]
1.5 T 5.0 T1: sag | T2: ax
| FLAIR
– –
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were also included. We examined both prevalence (i.e.
proportion of patients with SCIs at one particular time)
and incidence (i.e. rate at which patients develop SCIs
over time). One study in 23 individuals found a SCI preva-
lence rate that extremely deviated from the prevalences
observed in other included studies, with a Z-score of 2.7
[51]. The prevalence of SCIs was most probably much
higher in this study, due to the use of a 7-T MRI scan. To
not distort the results, this study was deemed an outlier
and excluded from frequency analyses.







Sequence MRI criteria for SCIs detection Clinical criteria for SCIs
Onofri et al.
2012 [41]
1.5 T 5.0 FLAIR: ax – –
Pegelow et al.
2001 [42]





– – – Abnormal MRI No neurological deficit
Quinn et al.
2013 [43]
– – FLAIR Signal abnormality ≥ 3 mm in one
dimension, visible on at least two
views of T2 FLAIR
Normal neurological examination or
absence of neurological symptoms that
correlate with lesion location
Schatz et al.
2006 [44]
1.5 T 5.0 T1: sag | T2:
ax
Area of abnormal hyperintensity,









1.5 T 5.0 T1: sag, ax | T2 |
FLAIR: ax






1.0 T 5.0 T2: ax, cor |
FLAIR: ax, cor
Focal (< 1 cm) or multiple (> 1 cm)
high-intensity lesions on T2 or FLAIR




1.5 T 5.0 or 3.0 T1: ax | T2:
ax |FLAIR: ax
Evidence of ischaemia, including
lacunar infarction, encephalomalacia,
atrophy or leukoencephalopathy
Absence of a clinical history of stroke
Tewari et al.
2018 [49]
– – FLAIR Area of abnormal hyperintensity
≥ 3 mm in diameter and visible in at
least two planes of T2 (ax and cor)
No history or physical findings of a





3.0 T – 3D FLAIR Multiple (> 1) hyperintensities ≥ 5 mm –
Van der Land
et al. 2015 [51]
3.0 and 7.0 T – T1 |FLAIR: ax Areas of abnormal hyperintensity No history or physical findings of a
focal neurological deficit
Van der Land
et al. 2016 [52]
3.0 T 5.0 T2 |FLAIR Hyperintensity of variable size in the
white matter on FLAIR, without
cavitation




1.5 T – T1 | T2 | PD Area of abnormal hyperintensity at
least 5 mm on T2 and PD, with




1.5 T 5.0 T1: ax | T2: ax Area of abnormal hyperintensity
on T2
No history of neurological symptoms
compatible with overt stroke
Wang et al.
2008 [55]
1.5 T 5.0 T1: ax |FLAIR:
ax, cor
Area of abnormal hyperintensity on
T2, consistent with an ischaemic




1.5 T 5.0 T2: ax – –
Zafeiriou et al.
2004 [57]
1.5 T T1: ax Area of abnormal hyperintensity on
T2
–
MRI magnetic resonance imaging, SCIs silent cerebral infarctions, ax axial, cor coronal, sag sagittal, T1 T1-weighted, T2 T2-weighted, FLAIR fluid-attenuated
inversion recovery, PD proton density
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Prevalence of SCIs in HbSS and HbSβ0 genotypes
Most studies (n = 27) were performed in patients with
HbSS and HbSβ0 SCD (n = 2789), with overall preva-
lence rates ranging from 5.6 to 80.6% (Table 2). The
pooled prevalence of SCIs in HbSS and HbSβ0 genotypes
was 29.5% (95% CI 25.2–33.9).
Data from the included studies showed a statistically
significant association between increasing mean age of
the study population and mean SCI prevalence: β = 1.0%
increase in SCI prevalence for 1 year increase in mean
age (95% CI 0.5–1.6), p = 0.001, Fig. 2. When corrected
for publication year, study design (i.e. prospective cohort
study or retrospective cohort study), sample size and
field strength, the association between age and SCI
prevalence remained significant: β = 0.8% (95% CI 0.2–
1.5), p = 0.012.
Prevalence of SCIs in other genotypes and healthy controls
Twelve studies separately reported the prevalence of
SCIs in other SCD genotypes, i.e. HbSC, HbSβ+ (total
n = 254), and in healthy controls (n = 266) [10, 21, 22,
26, 28–30, 33, 35, 40, 50, 53]. The mean pooled preva-
lence of SCIs was 9.2% (95% CI 2.9–15.4) in patients
with HbSC and HbSβ+, which was significantly lower
compared to patients with HbSS and HbSβ0 SCD (p =
0.006, Fig. 3).
In nine studies (total n = 266), the prevalence of SCIs
was reported for controls [21, 22, 28–30, 35, 40, 50, 53].
Control subjects were mostly matched adolescents or
young adult family members, with a mean age varying
between 9.8 and 37.4 years. Although healthy, informa-
tion regarding possible HbS carrier status was not pro-
vided for all controls. Sickle cell trait (HbAS genotype)
Table 2 Prevalence of silent cerebral infarcts in HbSS and HbSβ0 sickle cell disease patients
Author (year) Study design Sample size Mean age (years) Field strength (T) Prevalence SCIs (%)
Abboud et al. 2011 [19] PCS 77 12.3 NA 26.6
Arkuszewski et al. 2014 [20] PCS 67 8.8 3.0 37.7
Asbeutah et al. 2014 [21] PCS 40 10.1* 1.5 10
de Blank et al. 2010 [24] RCS 254 10.6 NA 30.7
Brousse et al. 2017 [25] PCS 59 11.4 NA 13.6
Brown et al. 2000 [26] PCS 48 9.8* NA 22.9
Calvet et al. 2017 [27] RCS 83 43.3 3.0 49.4
Ford et al. 2017 [30] PCS 22 27 NA 54.5
Ford et al. 2018 [31] PCS 1061 NA NA 27
Guilliams et al. 2015 [33] RCS 168 NA 1.5/3.0 27.4
Gyang et al. 2011 [34] RCS 8 15 NA 50
Kassim et al. 2016 [36] RCS 60 30 NA 53.3
Kwiatkowski et al. 2009 [6] RCS 65 3.6 1.5 27.7
Marouf et al. 2003 [67] PCS 35 26.9 NA 20
Mercuri et al. 1995 [39] PCS 11 9.3 1.0 45.5
Nottage et al. 2016 [68] PCS 50 9.4 NA 38
Oguz et al. 2003 [40] PCS 18 8.7 1.5 5.6
Pegelow et al. 2002 [10] RCS 266 8.3* NA 21.8
Schatz et al. 2005 [44] PCS 20 12.2** 1.5 40
Silva et al. 2009 [46] PCS 46 26.8 1.5 56.5
Tewari et al. 2018 [49] PCS 51 12.4** NA 37.3
Václavů et al. 2019 [50] PCS 36 31.9 3.0 80.6
Van der Land et al. 2015 [51] PCS 10 23 3.0/7.0 50
Van der Land et al. 2016 [52] PCS 34 12.1 3.0 41.2
Vichinsky et al. 2010 [53] PCS 141 31.6 1.5 28.9
Wang et al. 1998 [54] PCS 36 1.5 1.5 8.3
Wang et al. 2008 [55] PCS 23 1.1 1.5 13
SCIs silent cerebral infarctions, PCS prospective cohort study (including case-control and randomized controlled trial), RCS retrospective cohort study, NA
not available
*Only the mean age for the full sample was provided, not separately for HbSS and HbSβ0 thalassemia patients
**Only the mean age for the SCI-affected and SCI-unaffected group separately was provided, not for the full sample
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was reported in 40 control subjects, whereas 132 sub-
jects were explicitly reported not to have sickle cell trait
(i.e. HbAA). Carrier status was unknown for the
remaining 94 controls. Additional Table 1 shows the
prevalence of SCIs and information regarding carrier
status for control subjects. Control subjects showed a
mean pooled prevalence of SCIs of 9.8% (95% CI − 0.5–
20.1). Surprisingly, there was no significant difference
(p = 0.915) in the mean pooled prevalence of SCIs be-
tween patients with HbSC and HbSβ+ SCD and controls
(Fig. 3).
SCI incidence
Incidence data in different age groups was scarce, due to
the inherent difficulties of longitudinal studies. Only four
studies provided estimates ranging from 3.1 to 13.6% per
year [10, 23, 34, 43]. In addition, the majority of studies
did not address the first presentation of SCIs in
young children, as most studies included patients
older than 6 years of age because younger children
often need sedation during MRI studies. However,
four studies did report results from very young chil-
dren, showing that SCIs begin to develop in children
as young as 1 year of age [6, 54, 55, 59].
Risk factors
Thirty-three studies were identified that examined the
risk factors for SCIs in patients with SCD (Table 3).
Remarkably, for most risk factors, equal numbers of
studies were found showing significant as well as insig-
nificant associations. Furthermore, conflicting results
were founded for two risk factors, i.e. mean systolic
blood pressure and MCV with studies finding positive
associations and studies finding negative associations.
Seven studies reported nine ‘independent’ risk factors
in multivariable analyses (Table 4). Of these risk factors,
only systolic blood pressure, haemoglobin level and
foetal haemoglobin percentage were shown to be signifi-
cant in more than one model. It was not possible to esti-
mate a pooled odds ratio (OR) or a mean difference due
to the small number of studies available.
Clinical impact
By definition, SCIs do not lead to overt neurological
symptoms. However, they are associated with more
subtle neurological deficits and an increased risk of sub-
sequent overt stroke [10–12].
Risk of cognitive decline
Cognitive deficits have been demonstrated in patients
with SCD using validated tests for general intelligence,
visual processing and academic achievement. Several
studies have reported poorer global intellectual function
in patients with SCIs [12, 22, 26, 32, 38, 64, 69, 76, 77].
Of the nine included studies in which an association be-
tween lower cognitive test scores and SCIs was evalu-
ated, such an association was found in eight. The CSSC
D study showed that children with SCD and SCIs scored
lower on full-scale intelligence quotient (IQ) (p < 0.003),
verbal IQ (p < 0.01), reading (p < 0.04) and math achieve-
ment tests (p < 0.04), than children with normal MRI
findings [12, 76].
Although overt stroke is an obvious cause of neuro-
logic abnormality and cognitive impairment [12], cogni-
tive deficits also occur in patients without evidence of
focal brain injury [53, 69, 78–80]. The CSSCD study
found that children with a persistently normal cerebral
MRI during the entire 10-year study period still pre-
sented with a decline of 1.5 IQ points per year [76]. In
addition, Hogan et al. showed that lower intellectual
Fig. 2 The mean prevalence of silent cerebral infarcts, by mean age
in patients with HbSS and HbSβ0 sickle cell disease. Linear regression
analysis was used to analyse the association between age and
SCI prevalence
Fig. 3 Comparison of the mean prevalence of silent cerebral infarcts
in different sickle cell disease genotypes versus healthy controls.
Univariate general linear models were used to compare the mean
pooled prevalence of SCIs between the two groups.*HbSC,
HbSβ+, HbSE
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functioning in children with SCD is partly explained
by chronic hypoxia due to severe anaemia. This sug-
gests that patients with normal MRI results may also
have a constrained intellectual development [81].
Other studies conformingly show that low haemoglo-
bin levels are a stronger predictor of neurocognitive
function than SCIs [53, 69, 78].
Risk of recurrent and progressive SCIs or overt stroke
SCIs are associated with an increased risk of subsequent
stroke in patients with SCD. The CSSCD study was the
first to report that the presence of SCIs is a risk factor
for additional neurological injury, with a 14-fold in-
crease in the risk of overt stroke, as 25% of children
with SCIs presented with new or enlarged lesions at
follow-up [10]. These findings have been confirmed in
more recent publications, including in a study in
which SCIs in very young children were associated
with subsequent progressive ischaemia and a higher
risk of overt stroke [59]. Further supportive of pro-
gressive ischaemia are the studies which report that
many patients with SCIs present with more than one
lesion [20, 21, 27, 28, 32, 33, 36, 50, 77].
Discussion
Challenges regarding reviewed studies
Detection of SCIs is dependent upon the sensitivity and
specificity of cerebral MRI scans and the definition of
the radiological appearance. Importantly, advances in
MRI technology lead to major heterogeneity when
studying the prevalence, incidence and risk factors for
the occurrence of SCIs in SCD. However, despite advan-
cing neuroimaging technologies and therefore possible
enhanced detection of SCIs, we did not find a rise in SCI
prevalence in included studies over the years. MRI pa-
rameters varied widely in the studies included in this
systematic review, with magnetic field strength ranging
from 0.6 to 7.0 T and slice thickness ranging from 1.0 to
6.0 mm. One study used 7-T MRI and identified many
more intracerebral lesions when compared to 3-T MRI
scanning, both in patients and in controls, with SCI
prevalence rates as high as 90% and 70%, respectively
[51]. Although this study was excluded from our analysis
as an outlier due to the extreme Z-score in order to not
distort the overall analysis, it does suggest that SCI
prevalence rates may actually be much higher when pa-
tients are screened with high-field magnet strength MRI.
However, in accordance with the variability in SCI defi-
nitions utilized in the literature, the same study also ob-
served that almost all lesions were smaller than 5mm,
with a majority even smaller than 3mm [51]. When so
small, lesions may be easily confused with dilated peri-
vascular spaces, also known as Virchow-Robin spaces,
which may lead to an overall overestimation in preva-
lence [82].
Most studies did not define whether the performed
MRI scans were reviewed with knowledge of patients’
medical histories and whether or not neurological exam-
ination was performed by a neurologist. Because infarcts
are classified as silent, if they—by definition—lack
Table 4 Summary of the risk factors for MRI-defined silent cerebral infarcts in sickle cell disease analysed in multivariate models
Risk factors OR/HR* (95% CI) p value Study
Male sex NA 0.030 DeBaun et al. 2012** [70]
Higher SBP NA 0.018 DeBaun et al. 2012** [70]
NA 0.015 Sarnaik et al. 2009 [74]
Higher WBC count 3.23 (1.24–14.37) 0.016 Kinney et al. 1999 [72]
Lower Hb level 1.75 (1.14–2.78) 0.011 Bernaudin et al. 2011 [23]
2.88 (1.05–7.87) 0.039 Bernaudin et al. 2015 [58]
NA 0.001 DeBaun et al. 2012** [70]
Lower HbF% 0.84 (0.72–0.97) 0.02 Calvet et al. 2017 [27]
NA 0.038 Sarnaik et al. 2009 [74]
Apolipoprotein A1 0.96 < 0.05 Strouse et al. 2009 [75]
Extracranial stenosis 3.11 (1.10–8.85) 0.033 Bernaudin et al. 2015 [58]
SEN β-globin haplotype 2.53 (1.03–6.23) 0.044 Kinney et al. 1999 [72]
VOC rate 0.53 (0.30–0.95) 0.034 Kinney et al. 1999 [72]
Acute anaemic event 3.39 (1.01–11.34) 0.048 Bernaudin et al. 2015 [58]
Seizure 14.4 (1.5–141) 0.023 Kinney et al. 1999 [72]
Abbreviations: NA not available, SBP systolic blood pressure, WBC white blood cell, Hb haemoglobin, HbF foetal haemoglobin, SEN Senegal, VOC
vaso-occlusive crisis
*Results reported as odds ratio (OR) or hazard ratio (HR)
**This reduced multivariate logistic regression model was overall statistically significant (x2 = 24.41, df = 3, p = .001)
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stroke-like symptoms, a haematologist may miss subtle
neurological anomalies that may classify as a deficit in
neurological examination by a neurologist.
We excluded studies with patients who had a history
of overt stroke to ensure that no radiological apparent
stroke was mistaken as SCIs. However, as SCIs have
been identified as a risk factor for progression of SCIs
and development of overt stroke, a large portion of
stroke patients will also have additional SCIs. This was
not taken into consideration in our analyses, and there-
fore, this exclusion criterion may have led to an under-
estimation in the prevalence of SCIs.
Most studies consisted of a heterogeneous group of
patients. A few studies included individual patients on
varying treatment regimens such as hydroxyurea medi-
cation or chronic red cell blood transfusions. Although
currently there is no high-level evidence supporting
these therapies as preventive for the development of
SCIs [7], estimations of SCI prevalence may have been
influenced by specific treatment regimens.
Finally, the absence of robust findings regarding the
risk factors for the occurrence of SCIs is most probably
due to the small patient sample sizes as well as weak
associations. Tabulating the results in our systematic re-
view was challenging due to the differences in defini-
tions, heterogeneity of patients and treatment regimens
and varying measurement methods and statistical ana-
lyses of many of the risk factors. Few studies explicitly
stated the variables that were adjusted for in the multi-
variable analyses. In addition, the extent to which vascu-
lar risk factors are actually dependent upon one another
is debatable, and interactions between the risk factors
may have been overlooked by used analytic methods.
Future directions for research
The study limitations mentioned above provide several
considerations for future studies. In particular, the use
of a consistent definition of SCIs is crucial. We suggest a
minimal MRI field strength of 1.5 T with 3-mm-thick
slices or thinner and at minimum the inclusion of FLAI
R sequences. More specifically, lesions less than 3 mm in
size should be excluded to minimize misdiagnosis of
SCIs. In addition, reviewing of MRI scans as well as pa-
tient examination should be performed by experienced
specialists.
Importantly, most studies were performed in children
with SCD and limited attention has been given to adult
patients. Longitudinal studies in patients over 16 years of
age are necessary to understand the natural course of
SCIs and their clinical relevance in adults with SCD.
When designing future studies, it is essential to include
matched control groups of healthy individuals, as sib-
lings of patients with SCD often have sickle cell trait
which is reported to possibly also impact cognition [48,
78, 83, 84]. Moreover, it is important to realize that
healthy individuals also accumulate white matter hyper-
intensities with increasing age, which do not necessarily
reflect SCIs. Epidemiological estimates have shown that
the prevalence of SCIs detected by MRI screening is be-
tween 10 and 20% in the general population, with a
strong association between SCI prevalence and age of
the population assessed [82]. Unfortunately, the preva-
lence and incidence data on SCIs in populations younger
than 45 years are lacking. Appreciation for possible SCIs
in healthy children and young adults is essential to bet-
ter understand SCI implications in SCD.
Lastly, further research is needed to determine the risk
factors for and mechanisms of cognitive impairment in
SCD in the absence of overt infarcts and SCIs. To this
end, it is essential to differentiate between disease-
related effects on brain function, indirect effects of
chronic illnesses and psychosocial and socioeconomic
factors [80]. This requires both longitudinal quantitative
MRI and neuropsychological studies in combination
with demographic and clinical variables.
Conclusions
SCIs are common in patients with HbSS and HbSβ0
SCD with a weighted prevalence of 29.5%. SCIs occur
more often in patients with HbSS and HbSβ0 SCD when
compared to other SCD genotypes and healthy controls,
as respectively SCIs were found in 9.2% of HbSC and
HbSβ+ patients and in 9.8% of controls.
Although the prevalence estimates varied widely
across studies, data from this systematic review show
a significant association between increasing patient
age and SCI prevalence, which is consistent with an
effect of age on cerebrovascular disease in SCD. Risk
factor analyses showed no clear association between
prevalence of SCIs and studied risk factors. Additional
neuroimaging of patient populations with TCD, MRA
or ASL may elucidate the pathogenesis and risk fac-
tors for the development of SCIs in SCD long term.
Larger, prospective and controlled clinical, neuro-
psychological and neuroimaging studies are needed to
understand how SCD and SCIs negatively affect cog-
nition. Such studies may also provide a starting point
for the identification of potential targets for prevent-
ive therapies by a better understanding of underlying
pathophysiological mechanisms.
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